Article

RA Task Force Recommendations and the Management of Comorbidities

(AUDIO) How RA comorbidities might be addressed differently in light of new international task force recommendations is the subject of this discussion from Stephen A. Paget, MD, Chairman of the Division of Rheumatology at the Hospital for Special Surgery in New York.

How RA comorbidities might be addressed differently in light of new international task force recommendations is the subject of this discussion from Stephen A. Paget, MD, Chairman of the Division of Rheumatology at the Hospital for Special Surgery in New York.

RA Task Force Recommendations and the Management of Comorbidities

 

Related Videos
John Stone, MD, MPH: Continuing Progress With IgG4-Related Disease Research
Philip Conaghan, MBBS, PhD: Investigating NT3 Inhibition for Improving Osteoarthritis
Rheumatologists Recognize the Need to Create Pediatric Enthesitis Scoring Tool
Presence of Diffuse Cutaneous Disease Linked to Worse HRQOL in Systematic Sclerosis
Alexei Grom, MD: Exploring Safer Treatment Options for Refractory Macrophage Activation Syndrome
Jack Arnold, MBBS, clinical research fellow, University of Leeds, Leeds Institute of Rheumatic and Musculoskeletal Medicine
John Tesser, MD, Adjunct Assistant Professor of Medicine, Midwestern University, and Arizona College of Osteopathic Medicine, and Lecturer, University of Arizona Health Sciences Center, and Arizona Arthritis & Rheumatology Associates
Gaith Noaiseh, MD: Nipocalimab Improves Disease Measures, Reduces Autoantibodies in Sjogren’s
Laure Gossec, MD, PhD: Informing Physician Treatment Choices for Psoriatic Arthritis
Søren Andreas Just, MD, PhD: Developing AI to Mitigate Rheumatologist Shortages for Disease Assessment
Related Content
FDA Approves Ustekinumab (STELARA) Biosimilar for Crohn’s, UC, Psoriasis, PsA
December 2nd 2024

FDA Approves Ustekinumab (STELARA) Biosimilar for Crohn’s, UC, Psoriasis, PsA

Victoria Johnson
Emerging Agents in the Treatment of Rheumatic Diseases
October 2nd 2023

Emerging Agents in the Treatment of Rheumatic Diseases

Nehad Soloman, MD, FACR Andrew Sharobeem, DO, FACR Philip J. Mease, MD
PEGylated Uricase Well-Tolerated, Demonstrates Dose-Dependent Urate-Lowering
November 28th 2024

PEGylated Uricase Well-Tolerated, Demonstrates Dose-Dependent Urate-Lowering

Victoria Johnson
Challenges with Step Therapy Protocols in Treating Rheumatoid Arthritis
August 31st 2023

Challenges with Step Therapy Protocols in Treating Rheumatoid Arthritis

Nehad Soloman, MD, FACR Andrew Sharobeem, DO, FACR John B. Boone, MD, FACR Madelaine Feldman MD, FACR
Lihi Eder, MD, associate professor of medicine, Women’s College Hospital and University of Toronto, Canada
November 26th 2024

Guselkumab Similarly Efficacious Among Male, Female Patients With PsA

Victoria Johnson
Urate-Lowering Therapy Remains Tolerable in Patients with Gout, CKD | Image Credit: ResearchGate
November 25th 2024

Urate-Lowering Therapy Remains Tolerable in Patients with Gout, CKD

Connor Iapoce
© 2024 MJH Life Sciences

All rights reserved.